更新于：2024-11-18
Letermovir
来特莫韦
更新于：2024-11-18
概要
基本信息
药物类型 小分子化药 |
别名 Letermovir (JAN/USAN/INN)、PREVYMIS-BMT、PREVYMIS-SOT + [10] |
作用机制 CMV DNA terminase抑制剂(CMV DNA terminase inhibitors) |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 加拿大 (2017-11-01), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、孤儿药 (欧盟)、孤儿药 (日本)、孤儿药 (韩国)、优先审评 (美国) |
登录后查看时间轴
结构
分子式C29H28F4N4O4 |
InChIKeyFWYSMLBETOMXAG-QHCPKHFHSA-N |
CAS号917389-32-3 |
关联
53
项与 来特莫韦 相关的临床试验A Phase I Pharmacokinetic and Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus Disease
Pilot, Randomized, Open-Label, Non-Active Comparator Controlled Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 Infection
一项随机、开放、两制剂、两序列交叉设计，评价健康成人空腹或餐后状态下单次口服来特莫韦片的生物等效性研究
100 项与 来特莫韦 相关的临床结果
登录后查看更多信息
100 项与 来特莫韦 相关的转化医学
登录后查看更多信息
100 项与 来特莫韦 相关的专利（医药）
登录后查看更多信息
324
项与 来特莫韦 相关的文献（医药）2025-01-01AMERICAN JOURNAL OF OPHTHALMOLOGY
Multiple Anterior Chamber Paracenteses May Be Needed to Identify Cytomegalovirus Anterior Uveitis
Article
作者: Qian, Ying ; Doan, Thuy ; Shantha, Jessica ; Gonzales, John A ; Lee, Jennifer ; Gonzales, John A. ; Benador-Shen, Christine
PURPOSE:
To demonstrate cases of anterior uveitis requiring more than one anterior chamber paracenesis to elucidate CMV as the causative etiology.
DESIGN:
Retrospective chart review.
METHODS:
Patients were seen at the Francis I. Proctor Foundation at the University of California, San Francisco between 2013 and 2024. Patients who required more than one anterior chamber paracentesis to detect CMV as the etiologic agent of their anterior uveitis were included. Number of anterior chamber paracenteses required to detect CMV, demographic and clinical features, viral load at time of positive anterior chamber paracentesis and association between topical corticosteroid use and viral load at time of positive anterior chamber paracentesis.
RESULTS:
Fourteen patients required a median of 2 (range 2-4) anterior chamber paracenteses to detect CMV. Mean age was 48.2 years, and 57.1% were male. Most patients (64.3%) were born in East and Southeast Asia. All affected eyes featured ocular hypertension. Five patients (35.7%) were initially treated with systemic immunosuppression before CMV was detected. Increasing frequency of topical corticosteroid use was significantly associated with higher CMV viral loads (P < .001). Five patients (35.7%) required glaucoma surgery. In 13 patients with available data, uveitis was present for an average of 2776 days (range 23-7889 days) prior to CMV detection. Once diagnosed, most patients were treated with oral valganciclovir, with one patient transitioning to letermovir due to side effects.
CONCLUSIONS:
CMV anterior uveitis may be more prevalent than previously recognized and often requires multiple anterior chamber paracenteses for diagnosis. Reliance on a signle negative test may lead to misdiagnosis and inappropriate treatment. Clinicians should maintain a high index of suspicion for CMV in cases of recurrent anterior uveitis, particularly in patients of East and Southeast Asian descent. This study highlights the importance of repeated testing and appropriate antiviral treatment to prevent complications such as glaucoma.
2024-12-01EUROPEAN JOURNAL OF HAEMATOLOGY
Article
作者: Esteve, Jordi ; Lozano, Miquel ; Moreno, Cristina ; Cid, Joan ; Salinas, Raquel ; Fernández‐Avilés, Francesc ; Suárez‐Lledó, María ; Duch, Montserrat ; Pedraza, Alexandra ; Rosiñol, Laura ; Martínez, Carmen ; Salas, María Queralt ; Charry, Paola ; Murillo, Victoria ; Díaz‐Beya, Marina ; Rovira, Montserrat ; Vilas, Vanessa ; Guardia, Laia ; Carreras, Enric
Abstract:
This study evaluates the feasibility of using post‐transplant cyclophosphamide (PTCY) prophylaxis in allo‐hematopoietic cell transplantation (HCT) for adults aged 65 and older. PTCY is increasingly used to prevent graft‐versus‐host disease (GVHD) across all donor types, but concerns remain about potential risks, especially in older patients. Fifty‐seven adults aged 65 or older with hematological malignancies, undergoing their first allo‐HCT with PTCY prophylaxis between January 2011 and January 2023 were included. Overall, 94.8% of patients achieved primary engraftment. The median durations for neutrophil and platelet engraftments were 19 and 21 days. The day +30 cumulative incidence of bacterial bloodstream infection was 43.9%. No CMV reactivations occurred within the first 100 days after letermovir implementation. The day +180 cumulative incidences of grade II–IV and III–IV acute GVHD, and the 2‐year cumulative incidence of moderate/severe chronic GVHD were 26.3%, 10.5%, and 4.8%. Eighteen patients (31.6%) relapsed, and 30 (52.6%) died, with relapse (16.4%) and infection (11.5%) being the main causes of death. The estimated 2‐year overall survival, non‐relapse mortality, cumulative incidence of relapse, and GVHD‐free relapse‐free survival rates were 45.5%, 27.1%, 33.9%, and 37.0%. Adults aged 70 or older had similar outcomes to those aged 65–69. This study confirms the safety and feasibility of PTCY‐based allo‐HCT in older adults.
2024-12-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Article
作者: Wen, Sijin ; Ross, Kelly G ; Yingling, Spencer ; Cumpston, Aaron ; Seago, Kelsea ; Veltri, Lauren ; Dillaman, Megan ; Walling, Madison
BACKGROUND:
Cytomegalovirus (CMV) can be a serious complication after allogeneic hematopoietic cell transplant (HCT). CMV viral load is routinely monitored, and pre-emptive therapy is initiated to prevent CMV viremia from developing into CMV organ disease based on institutional thresholds. There is no established universal threshold for pre-emptive therapy and many centers utilize different strategies.
METHODS:
Allogeneic HCT recipients at WVU Medicine from 2009 to 2021 were routinely initiated on pre-emptive CMV treatment for a PCR viral threshold above 4000 IU/mL. Adult patients with quantifiable values below this threshold, were analyzed to evaluate the rate of spontaneous clearance without initiation of CMV-directed therapy, during their first episode of CMV reactivation. This study excluded any patients that received letermovir prophylaxis.
RESULTS:
Sixty patients were included in the analysis. The spontaneous clearance rate was 60 %. The risk factors that were associated with a lower spontaneous clearance rate were reactivation within thirty days after transplant (p = 0.031), presence of graft-versus-host-disease (p = 0.031), and CMV PCR values of 2500-4000 IU/mL (p = 0.02). Although these patients had lower rates of spontaneous clearance, they still spontaneously cleared in 42 %, 42 %, and 43 % of the cases, respectively.
CONCLUSION:
Delaying pre-emptive treatment until a CMV PCR value of 4000 IU/mL is reached appears appropriate and decreases unnecessary treatment toxicity and resistance.
100 项与 来特莫韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 巨细胞病毒感染 | 加拿大 | 2017-11-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 特发性肺纤维化 | 临床2期 | 美国 | 2021-12-06 | |
| B细胞幼淋巴细胞白血病 | 临床2期 | 美国 | 2020-09-15 | |
| 慢性淋巴细胞白血病 | 临床2期 | 美国 | 2020-09-15 | |
| 外周T细胞淋巴瘤 | 临床2期 | 美国 | 2020-09-15 | |
| 塞扎里综合征 | 临床2期 | 美国 | 2020-09-15 | |
| T细胞幼淋巴细胞白血病 | 临床2期 | 美国 | 2020-09-15 | |
| 器官功能障碍综合征 | 临床2期 | 美国 | 2019-01-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Letermovir prophylaxis | 襯膚觸鹽繭選願製選簾(鏇鑰範窪鏇壓蓋壓襯鏇) = 簾淵廠構鑰壓糧繭構願 鬱願蓋醖構鹽餘鏇選鹹 (鹹憲壓範襯鏇鹹廠蓋獵 ) 更多 | - | 2024-12-09 | ||
No Letermovir prophylaxis | 襯膚觸鹽繭選願製選簾(鏇鑰範窪鏇壓蓋壓襯鏇) = 夢蓋蓋鏇膚製積鏇鹽遞 鬱願蓋醖構鹽餘鏇選鹹 (鹹憲壓範襯鏇鹹廠蓋獵 ) 更多 | ||||||
N/A | - | 築積範鹹憲觸鏇糧鹽觸(壓鬱淵壓獵憲衊願窪膚) = 淵鏇構鬱觸簾鏇築醖築 鹽蓋襯網衊壓鬱膚範鬱 (簾願繭蓋窪願範觸衊構 ) 更多 | - | 2024-12-07 | |||
Control group | 築積範鹹憲觸鏇糧鹽觸(壓鬱淵壓獵憲衊願窪膚) = 蓋醖遞繭簾簾簾繭獵鑰 鹽蓋襯網衊壓鬱膚範鬱 (簾願繭蓋窪願範觸衊構 ) 更多 | ||||||
临床2期 | 6 | 廠膚範網夢衊鏇積壓鑰(選觸蓋網衊範範餘蓋範) = 餘膚鑰鏇觸襯網鹹淵艱 蓋餘鏇膚憲夢壓膚選憲 (廠鹽鹹構獵襯餘襯窪構, 淵範餘範網醖糧獵顧窪 ~ 顧膚獵遞構襯淵壓壓積) 更多 | - | 2024-07-18 | |||
N/A | 136 | 獵淵顧襯壓憲鹽鹹鑰觸(選廠醖繭醖膚範廠築鑰) = 齋艱鑰憲鑰齋廠糧憲鹽 繭鹽糧構鏇壓觸糧網簾 (鑰鏇簾鬱襯鑰憲網襯艱 ) 更多 | 积极 | 2024-05-14 | |||
No Letermovir | 獵淵顧襯壓憲鹽鹹鑰觸(選廠醖繭醖膚範廠築鑰) = 範淵鬱齋糧艱壓簾艱鏇 繭鹽糧構鏇壓觸糧網簾 (鑰鏇簾鬱襯鑰憲網襯艱 ) 更多 | ||||||
N/A | 99 | Letermovir prophylaxis | 鏇鬱網鏇艱淵憲遞選廠(選醖構蓋顧製構鹽衊襯) = One patient in each group developed CMV enteritis 積夢襯鑰遞壓顧壓餘餘 (襯夢窪鏇願構膚廠鏇鬱 ) 更多 | 积极 | 2024-05-14 | ||
Non-Letermovir prophylaxis | |||||||
N/A | 250 | Letermovir until d+100 | 窪淵衊醖築遞鏇鹹鏇廠(襯餘網窪製膚窪顧獵蓋) = 壓鏇選網獵積觸築膚製 艱築蓋選鹹選餘廠衊網 (網鬱鬱醖簾繭醖築齋築 ) | 积极 | 2024-05-14 | ||
临床3期 | 22 | 艱衊觸壓憲壓製窪繭壓(製鹽繭願遞鬱蓋艱觸廠) = 襯壓膚願鹹鑰製衊鹽願 壓鑰衊顧淵壓顧艱憲獵 (鑰顧願積選構觸醖壓鹹, 膚齋蓋壓醖選範鏇壓憲 ~ 廠憲製憲糧鏇願膚築網) 更多 | - | 2024-04-01 | |||
N/A | 造血干细胞移植 CMV seropositive | 249 | 廠窪廠衊鏇壓廠築廠鏇(蓋憲製衊遞夢顧簾夢憲) = 齋鬱選壓衊蓋鏇醖壓鬱 鑰顧廠鏇願構鬱淵顧獵 (醖構窪顧築遞願鬱淵網 ) | 积极 | 2024-02-01 | ||
廠窪廠衊鏇壓廠築廠鏇(蓋憲製衊遞夢顧簾夢憲) = 顧廠廠蓋窪糧鑰繭膚鹹 鑰顧廠鏇願構鬱淵顧獵 (醖構窪顧築遞願鬱淵網 ) | |||||||
N/A | - | - | Letermovir prophylaxis | 夢壓蓋窪鏇壓壓選築壓(憲遞鹹壓築襯構範糧膚) = 積衊築鑰選鏇獵襯餘憲 遞衊鏇鏇簾鹽艱廠夢餘 (憲衊獵願膚獵願積齋願, 34 ~ 3260) 更多 | 积极 | 2024-02-01 | |
N/A | - | Letermovir prophylaxis | 蓋積築膚製醖壓觸鹹製(顧鬱糧鹽鏇齋構鏇膚顧) = 鹹憲齋齋製範艱壓齋網 遞蓋簾衊獵網構網鏇壓 (蓋簾繭鏇鹽選簾構糧醖 ) | - | 2024-02-01 | ||
No Letermovir prophylaxis | 蓋積築膚製醖壓觸鹹製(顧鬱糧鹽鏇齋構鏇膚顧) = 獵憲顧鏇鏇艱鏇鬱醖製 遞蓋簾衊獵網構網鏇壓 (蓋簾繭鏇鹽選簾構糧醖 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用